PDCD1 and lymphoma: Although PD-1/CTLA-4 blockade greatly decreased the growth rate of EBV-induced lymphomas in the cord blood humanized mouse model, and extended the survival of EBV-infected mice, this therapy alone did not ultimately prevent death due to EBV+ lymphoma.